Vanguard Group Inc Icosavax, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.95 - $15.79 $405,962 - $1.08 Million	-68,229 Reduced 3.59%	1,830,058 $28.8 Million
Q3 2023 Nov 14, 2023	BUY	$7.22 - $10.05 $6.73 Million - $9.37 Million	931,859 Added 96.42%	1,898,287 $14.7 Million
Q2 2023 Aug 14, 2023	BUY	$4.89 - $10.57 $185,546 - $401,068	37,944 Added 4.09%	966,428 $9.6 Million
Q1 2023 May 15, 2023	BUY	$5.62 - $11.51 $141,697 - $290,201	25,213 Added 2.79%	928,484 $5.39 Million
Q4 2022 Feb 10, 2023	BUY	$2.32 - $10.97 $172,028 - $813,425	74,150 Added 8.94%	903,271 $7.17 Million
Q3 2022 Nov 14, 2022	SELL	$3.09 - $9.21 $9,619 - $28,670	-3,113 Reduced 0.37%	829,121 $2.62 Million
Q2 2022 Aug 12, 2022	SELL	$5.7 - $10.33 $180,684 - $327,450	-31,699 Reduced 3.67%	832,234 $4.77 Million
Q1 2022 May 13, 2022	BUY	$4.41 - $22.5 $1.3 Million - $6.62 Million	294,065 Added 51.6%	863,933 $6.08 Million
Q4 2021 Feb 14, 2022	BUY	$21.07 - $34.98 $380,292 - $631,354	18,049 Added 3.27%	569,868 $13 Million
Q3 2021 Nov 12, 2021	BUY	$24.85 - $40.25 $13.7 Million - $22.2 Million	551,819 New	551,819 $16.3 Million

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.